

**For immediate release
3 November 2011**



BAC and GE Healthcare expand product offering with the addition of VIISelect Bioprocess media

Naarden, The Netherlands - 03 November 2011 – BAC BV, the leading provider of antibody based affinity purification technology, today announced the addition of a new bioprocess affinity chromatography resin to GE Healthcare Life Sciences' portfolio of custom-designed media. The FactorVII / FactorVIIa resin will be marketed under the name VIISelect and is the latest addition to our series of chromatography media developed for the purification of blood coagulants.

VIISelect started as a custom ligand design program to develop chromatography media for the highly selective purification of human FactorVII / FactorVIIa. Following the discovery, GE Healthcare and BAC worked closely with the customer to develop the final media suitable for cGMP production of Factor VIIa. The launch of VIISelect media now offers a ready-to-use solution for the manufacturing of recombinant FactorVII / FactorVIIa ensuring a high purity product in a single-step.

Factor VIIa plays an important role in the blood coagulation cascade and recombinant Factor VIIa is used to treat and prevent bleeding episodes in hemophilia A and B patients with inhibitors to Factor VIII or Factor IX, and in patients with acquired hemophilia. Increasingly it is being used to treat uncontrollable hemorrhages.

"I am very pleased that we now can offer VIISelect to the market in order to facilitate both efficient and quick purification of Factor VII by affinity based chromatography at both lab and Bioprocess scale." Says Henrik Ihre, Director of Custom Design Media at GE Healthcare Life Sciences.

"We are very excited about this new product launch, once again demonstrating the broad applicability of our CaptureSelect technology", commented Laurens Sierkstra, CEO of BAC, adding, "working together with GE Healthcare and industry partners has already resulted in a multitude of products that have been adopted for large scale manufacturing of biotherapeutics."

Following the success of VIISelect for the purification of Factor VIII, VIISelect complements the range of products designed to support the area of hemophilia.

—ENDS—

Notes to editors:

About BAC BV

BAC discovers, develops and manufactures affinity ligands and affinity purification products to support biopharmaceutical research and production. BAC's CaptureSelect affinity purification and separation products are provided for the discovery, preclinical and clinical manufacturing of therapeutic proteins, including antibodies and antibody fragments. These products enable a reduced time to market, increased purity and yield and an overall lower

cost of goods for biopharmaceutical drug development. BAC BV was established in 1995 as a Unilever subsidiary. Currently the Company employs 37 people with an R&D laboratory facility in Leiden and a state-of-the-art ISO 9001 certified manufacturing plant in Naarden, the Netherlands. For more information about BAC, visit our website at www.bacbv.com. For more information about CaptureSelect® products, visit our website at www.captureselect.com

For additional information, please contact:

BAC BV

College Hill Life Sciences
Dr Lynne Trowbridge, Dr Anastasios Koutsos
BAC@collegehill.com
+44 20-7457-2020